For patients with CAD, it is also necessary to receive uACR assessment early after discharge to identify high-risk patients and control their urinary protein levels using SGLT-2, ACE-inhibitors and statins [30–32]. This evidence concerns the gene SLC5A2 and coronary artery disorder.